Gitelman syndromeE26.8

Last updated on: 22.04.2021

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Aostosoma recessive disease associated with hypokalemic alkalosis, salt wasting, renewed blood pressure, hypomagnesemia, and hypocalciuria.

Occurrence/EpidemiologyThis section has been translated automatically.

The prevalence is estimated to be about 1:40,000 in populations of European origin, i.e. about 1% are heterozygous (recessive inheritance). It is thus one of the most common hereditary renal tubulopathies. Symptoms usually do not appear before the age of 6 years.

EtiopathogenesisThis section has been translated automatically.

Gitelman syndrome is inherited in an autosomal recessive manner.

In most patients, mutations are found in the SLC12A3 gene (solute carrier family 12 member 3, 16q13). It encodes the thiazide-sensitive Na-Cl cotransporter (NCC).

To date, >150 different NCC mutations of the gene have been described. They affect the sodium-chloride cotransporter in the distal tubule of the nephron.

In a few patients with Gitelman syndrome (as in type III of Bartter syndrome = classical type) mutations were found in the CLCNKB gene (localization: 1p36). This gene codes for the renal chloride channel B (ClC-Kb).

DiagnosisThis section has been translated automatically.

The diagnosis follows from the clinical symptoms and the biochemical changes (hypokalemia, metabolic alkalosis, hypomagnesemia and hypocalciuria).

TherapyThis section has been translated automatically.

Substitutive potassium and magnesium regulation; prostaglandin synthesis inhibitors; spironolactone or triamterene.

LiteratureThis section has been translated automatically.

  1. Fulchiero R et al (2019) Bartter syndrome and Gitelman syndrome. Pediatr Clin North Am 66:121-134.
  2. Knoers NV et al (2008) Gitelman syndrome. Orphanet J Rare Dis 3:22.

Last updated on: 22.04.2021